Taysha Gene Therapies
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TSHA and other ETFs, options, and stocks.About TSHA
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing.
CEOSean P. Nolan
CEOSean P. Nolan
Employees73
Employees73
HeadquartersDallas, Texas
HeadquartersDallas, Texas
Founded2019
Founded2019
Employees73
Employees73
TSHA Key Statistics
Market cap1.39B
Market cap1.39B
Price-Earnings ratio-14.25
Price-Earnings ratio-14.25
Dividend yield—
Dividend yield—
Average volume3.45M
Average volume3.45M
High today$5.24
High today$5.24
Low today$4.99
Low today$4.99
Open price$5.07
Open price$5.07
Volume3.00M
Volume3.00M
52 Week high$5.51
52 Week high$5.51
52 Week low$1.05
52 Week low$1.05
Stock Snapshot
Taysha Gene Therapies(TSHA) stock is priced at $5.05, giving the company a market capitalization of 1.39B. It carries a P/E multiple of -14.25.
During the trading session on 2025-12-07, Taysha Gene Therapies(TSHA) shares reached a daily high of $5.24 and a low of $4.99. At a current price of $5.05, the stock is +1.2% higher than the low and still -3.6% under the high.
Trading activity shows a volume of 3M, compared to an average daily volume of 3.45M.
Over the past 52 weeks, Taysha Gene Therapies(TSHA) stock has traded between a high of $5.51 and a low of $1.05.
Over the past 52 weeks, Taysha Gene Therapies(TSHA) stock has traded between a high of $5.51 and a low of $1.05.
Analyst ratings
100%
of 14 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own TSHA. This list is generated using Robinhood data, and it’s not a recommendation.